GRCE

Grace Therapeutics, Inc. (GRCE) - 10-Q Summary

Business Context and Reporting Period

Reporting Period: Quarter ended December 31, 2024 (Q3 2024).

Company Status: Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) is a clinical-stage biopharmaceutical company focused on rare and orphan diseases. In October 2024, the company completed a domestication from Canada to Delaware and changed its trading symbol to "GRCE."

Strategic Focus: The company has prioritized the development of its lead candidate, GTx-104 (an IV formulation of nimodipine for aneurysmal subarachnoid hemorrhage), while deprioritizing GTx-102 and GTx-101 pending additional funding or partnerships.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported no revenue for any period presented.

Material Changes vs. Prior Period

• Increased R&D Spend: Research and development expenses increased by $0.75 million (Q3) and $4.9 million (YTD) compared to the prior year periods. This increase is primarily attributed to the pivotal Phase 3 STRIVE-ON clinical trial for GTx-104.
• Derivative Warrant Liability: The change in fair value of derivative warrant liabilities resulted in a $1.2 million loss in Q3 2024 (vs. a $0.1 million gain in Q3 2023) due to stock price fluctuations. YTD, this resulted in a $0.6 million gain (vs. a $1.7 million loss in YTD 2023).
• Restructuring Costs: The company incurred $1.5 million in restructuring costs in the prior year (YTD 2023) related to workforce reductions. No restructuring costs were incurred in the current period.
• Cash Position: Cash and cash equivalents decreased by approximately $12 million from the beginning of the fiscal year (March 31, 2024) to December 31, 2024, driven by operating losses.

Guidance, Outlook, and Risks

• Clinical Milestones: The company announced that the Phase 3 STRIVE-ON trial for GTx-104 met its primary endpoint, showing a 19% reduction in clinically significant hypotension compared to oral nimodipine. Management plans to submit a New Drug Application (NDA) to the FDA in the first half of 2025.
• Recent Financing: In a subsequent event (February 2025), the company completed a private placement raising approximately $13.8 million in net proceeds. Management believes current cash plus these proceeds will sustain operations for at least 12 months.
• Liquidity Risk: The company has incurred operating losses since inception and expects to continue doing so. It will require additional capital beyond the 12-month runway to fund daily operations and commercialization efforts.
• Regulatory Risk: Success is heavily dependent on FDA approval of GTx-104. Failure to obtain approval or delays in the NDA process could materially impact the business.

Investor Verification Checklist

• Runway Confirmation: Verify the exact duration of the operating runway post the February 2025 private placement ($13.8M proceeds) against current burn rates.
• NDA Timeline: Confirm the specific submission date for the GTx-104 NDA within the "first half of 2025" guidance and potential FDA review timelines.
• Warrant Liability Impact: Monitor the fair value of outstanding derivative warrant liabilities, as stock price volatility significantly impacts reported net loss.
• Commercialization Plan: Review the company's strategy for building a sales force and commercial infrastructure for GTx-104, given the lack of internal manufacturing capabilities.
• Pipeline Deprioritization: Assess the likelihood of securing partnerships or funding to restart development of GTx-102 and GTx-101.